What was the primary driver for Amgen's significant revenue growth in the first nine months of 2003?

The primary driver for Amgen's substantial revenue growth was a significant increase in product sales, particularly from its key products Aranesp®, Neulasta®, and ENBREL®. These products showed strong demand and contributed significantly to the overall increase in top-line revenue.

How did the acquisition of Immunex impact Amgen's financial results in the reported periods?

The acquisition of Immunex in July 2002 had a major impact. In the prior year's nine-month period, Amgen recorded a substantial write-off of $2,991.8 million for acquired in-process research and development related to the Immunex acquisition, leading to a significant net loss. While this acquisition led to higher operating expenses in the current period due to amortization and integration costs, it also bolstered Amgen's product portfolio and pipeline, contributing to the strong revenue growth and a return to profitability in the nine months ended September 30, 2003.

What is the company's outlook on liquidity and capital resources?

Amgen believes its existing funds, cash generated from operations, and available debt and equity financing sources are sufficient to meet its working capital and capital expenditure needs for the foreseeable future, including supporting its stock repurchase program. The company also estimates significant capital expenditures for 2003, primarily related to new manufacturing and research facilities.

How did Amgen's stock repurchase program perform during this period?

Amgen continued its stock repurchase program, repurchasing $1,222.8 million worth of common stock during the nine months ended September 30, 2003. This program is primarily intended to offset the dilutive effects of employee stock option and stock purchase plans. As of September 30, 2003, approximately $619.3 million remained available for future repurchases.

AMGN 10-Q Quarterly Report Q3 FY2003 — Revenue, Net Income, EPS

Summary

Amgen Inc. reported strong revenue growth for the nine months ended September 30, 2003, with total revenues reaching $6,009.7 million, a significant increase from $3,756.9 million in the prior year period. This growth was primarily driven by substantial increases in product sales, notably from Aranesp®, Neulasta®, and ENBREL®. Despite the revenue surge, the company's financial results were heavily impacted by the acquisition of Immunex Corporation in July 2002. The prior year's nine-month period included a substantial write-off of acquired in-process research and development of $2,991.8 million, leading to a net loss of $1,848.3 million. In contrast, the current nine-month period shows a net income of $1,712.6 million, reflecting the successful integration and operational performance post-acquisition, although operating expenses have also increased due to higher R&D, SG&A, and amortization costs associated with the acquisition.

Key Highlights

1Total revenues surged to $6,009.7 million for the nine months ended September 30, 2003, up from $3,756.9 million in the same period last year, primarily driven by product sales.
2Product sales increased significantly to $5,630.5 million for the nine months ended September 30, 2003, compared to $3,369.6 million in the prior year, with Aranesp®, Neulasta®, and ENBREL® being key growth drivers.
3The company reported a net income of $1,712.6 million for the nine months ended September 30, 2003, a substantial turnaround from a net loss of $1,848.3 million in the corresponding period of 2002.
4Operating expenses increased significantly, notably due to a $2,991.8 million write-off of acquired in-process research and development in the prior year, and increased R&D, SG&A, and amortization in the current period.
5Cash provided by operating activities grew to $2,369.1 million for the nine months ended September 30, 2003, compared to $1,428.7 million in the prior year, indicating strong operational cash generation.
6The company repurchased $1,222.8 million of common stock during the nine months ended September 30, 2003, as part of its ongoing stock repurchase program.

AMGEN INC Quarterly Report for Q3 Ended Sep 30, 2003

Summary

Key Highlights

Frequently Asked Questions